What a mesenchymal stem cell actually does
The picture almost everyone has in mind — a cell that arrives, turns into new tissue and replaces it — is not what the research describes. What it does is stranger and more interesting: it signals.
For years, the way cell therapy was explained was a bricklaying metaphor: there is damaged tissue, new cells are delivered, and those cells fill the gap. It is a comfortable image and it is the one holding up most of the sector's marketing. The problem is that the research of the last two decades points in another direction.
When you track what happens to mesenchymal cells after they are administered, most of them do not stay. They do not engraft, they do not turn into the target tissue, and they do not persist for the time it would take to rebuild anything by substitution. And yet, in the models where an effect is observed, that effect exists. The obvious question is how.
The answer is chemical, not structural
The mechanism that concentrates the evidence today is called paracrine signaling: the cell does not build, it secretes. It releases a set of bioactive molecules — growth factors such as VEGF, cytokines, chemokines, extracellular matrix components and vesicles such as exosomes — and it is those molecules that act on the surrounding tissue.
Three concrete things are attributed to that secretion: promoting the formation of new blood vessels (angiogenesis), modulating the immune response in inflamed tissue, and changing the behavior of the cells that are already there. Put another way: the administered cell is not the repair material. It is the instruction.
A mesenchymal cell does not behave like a brick. It behaves like a message.
And a mechanism described later: passing on mitochondria
In recent years a mechanism has been added to the list that fits neither of the two previous metaphors. Mitochondrial transfer has been described: the mesenchymal cell hands mitochondria over to damaged neighboring cells, and with them returns their capacity to produce energy.
It is a relevant finding because it changes the kind of problem you can aim at. If the mechanism were only to replace tissue, the natural target would be structural injuries. If, in addition, the energetic function of a cell that is still alive but exhausted can be restored, the frame widens to conditions where the tissue is not broken but spent. In research it has been explored in settings such as acute respiratory distress and myocardial ischemia.
Why this changes the questions worth asking
If the effect does not depend on the cell staying, then the critical variable is not how many cells are administered: it is what they secrete and under what conditions. And there an uncomfortable fact appears for any catalog-style pitch: what a mesenchymal cell secretes depends on the environment it finds itself in. The same cell type, in inflamed tissue or in quiet tissue, does not release the same thing.
That turns the question "how many million cells does it carry?" into a far less useful question than it seems, and the question "what state is the tissue they are going to in?" into the one that actually matters. It is also why a prior assessment — inflammatory markers included — is not an administrative step before the procedure: it is part of the variable that determines the outcome.
- Most administered cells neither engraft nor persist.
- The described effect is attributed to what they secrete, not to what they replace.
- What they secrete changes according to the environment they land in.
- That is why the patient's inflammatory state is a datum of the treatment, not a preamble to it.
None of this makes cell therapy smaller. It makes it more specific. And a specific intervention requires knowing, beforehand, what is being intervened upon.
Where the evidence stands
What the evidence supports
- That paracrine function — what the cell secretes — is central to the described effect of mesenchymal cell therapies, rather than engraftment.
- That among the identified mediators there are growth factors, cytokines, extracellular matrix components and extracellular vesicles.
- That mitochondrial transfer from the mesenchymal cell to damaged cells has been described, with recovery of energetic function.
- That the profile of what the cell secretes changes with the microenvironment it finds itself in.
What it does not yet
- It does not allow anyone to claim that these mechanisms translate into a clinical benefit for a specific person with a specific condition.
- Much of what is described comes from preclinical models; the step to people is precisely where most hypotheses fall.
- There is no dose, route or cell source established as optimal in general terms.
- There is no evidence supporting the use of these therapies as an anti-aging intervention in healthy people.
Sources
- Effects of microenvironment and biological behavior on the paracrine function of stem cells Review of paracrine function and its dependence on the microenvironment.
- From bench to bedside: translating mesenchymal stem cell therapies through preclinical and clinical evidence Translational review, including mitochondrial transfer as a mechanism.
- Paracrine Factors Released by Stem Cells of Mesenchymal Origin: A Systematic Review of Pre-clinical Studies Systematic review of preclinical studies on paracrine factors.
This article is general information. It does not replace a medical assessment, and none of its statements should be read as an indication for treatment.
Your data, not an average.
Everything explained here only means something when it is applied to one specific person. That is the starting point.
See the Precision Assessment
